default author photo

Sarah Jannier

University of Strasbourg - Department of Hematology and Oncology

Strasbourg

France

  • University of Strasbourg - Department of Hematology and Oncology

SCHOLARLY PAPERS

1

DOWNLOADS

95

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Downloads 95 (715,072)

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Number of pages: 28 Posted: 14 Apr 2022
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne-Sophie Desfachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J. Brisse, Gudrun Schleiermacher, olivier delattre, Gaelle Pierron and Daniel Orbach
PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, Clocheville Hospital - Pediatric Onco-Hematology Service, Aix-Marseille University - Assistance Publique-Hopitaux de Marseille, Gustave Roussy, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, Université d'Amiens - Department of Oncology-Hematology and Pediatric Immunology, University of Strasbourg - Department of Hematology and Oncology, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, University of Lille II - Centre Oscar Lambret, PSL Research University - Institut Curie, Gustave Roussy, University of Claude Bernard Lyon 1 - Centre Léon Bérard, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie and PSL Research University - SIREDO Oncology Center
Downloads 53 (1,049,673)

Abstract:

Loading...

Neurotrophic Tropomyosin Receptor Kinase, Fusion Transcript Tumor, TRK Inhibitor, Infantile Fibrosarcoma, burden of therapy.

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Number of pages: 20 Posted: 10 May 2022
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne-Sophie Desfachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J. Brisse, Gudrun Schleiermacher, olivier delattre, Gaelle Pierron and Daniel Orbach
PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, Clocheville Hospital - Pediatric Onco-Hematology Service, Aix-Marseille University - Assistance Publique-Hopitaux de Marseille, Gustave Roussy, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, Université d'Amiens - Department of Oncology-Hematology and Pediatric Immunology, University of Strasbourg - Department of Hematology and Oncology, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, University of Lille II - Centre Oscar Lambret, PSL Research University - Institut Curie, Gustave Roussy, University of Claude Bernard Lyon 1 - Centre Léon Bérard, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie and PSL Research University - SIREDO Oncology Center
Downloads 42 (1,183,247)

Abstract:

Loading...

Neurotrophic Tropomyosin Receptor Kinase, Fusion Transcript Tumor, TRK Inhibitor, Infantile Fibrosarcoma, burden of therapy.